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Development of agents to target oncogenes and the intracel-
lular signalling pathways in which their products participate
is already underway (Lemoine, 1992). Inhibitors of tyrosine
and serine/threonine kinases, inhibitors of growth factor
receptor binding, and agents acting on phospholipid meta-
bolism have all received attention (for reviews see Gullick,
1990; Grunick, 1991). This review focuses on what have been
called the informational molecules: the nucleic acids DNA
and RNA.
The potential for targeting processes in transcription and
translation through antisense technology stems from the
specificity conferred by nucleic acid base-pairing. It might be
easier to design a nucleic acid-based drug than drugs
targeting proteins simply because nucleic acids are less struc-
turally complex. A further perceived advantage of nucleic
acid-based targeting is that by intervention at an earlier stage
of gene expression, a more efficient drug (on a comparative
molar basis) will result. This review seeks to highlight some
of the approaches now being explored and the difficulties
which must be overcome before antisense agents become a
practical proposition for cancer therapy.
The antisense strategy
In principle the use of an antisense agent is exceedingly
simple. The major premise is the potential precise targeting
afforded by strand hybridisation. The shortest sequence
which is likely to be unique within the mRNA pool of a
human cell is on average 13 bases and within DNA 17 bases
(discussed in more detail later). It is generally assumed that
only a perfect match between the antisense agent and its
target will lead to inactivation of the target. Although there
is both theoretical (Herschlag, 1991) and experimental
(Woolfe et al., 1992) evidence that this may not always be the
case, there is evidence that the broad principle of antisense
inhibition of gene expression is valid.
With the goal of selective inhibition of gene expression,
there are a number of strategies in which antisense agents
might be employed. The most obvious is the binding of an
antisense agent to a target RNA molecule, either the cyto-
plasmic mRNA, or its nuclear localised precursor, hnRNA.
The latter may have particular advantages over mature cyto-
plasmic mRNA. First, the hnRNA pool size is likely to be
much smaller than that of cytoplasmic mRNA, consequently
the intracellular concentration of the antisense agent required
to block expression may be significantly lower. Second,
attacking intron-exon junctions may afford a higher degree of
gene specificity. However, the approach which has undoubt-
edly received most experimental attention has been the use of
synthetic antisense oligodeoxynucleotides as specific inhib-
itors of mRNA translation.
The second approach is to use specific oligodeoxynucleo-
tides as anti-gene agents, blocking the flow ofgenetic inform-
ation at a stage prior to transcription. Binding at the DNA
to form a triple helix can be manipulated to produce irrever-
sible binding, or even selective cleavage, leading to a loss of
gene expression or cell death.
A third approach comes from the realisation that partic-
ular nucleic acid sequences must be recognised by proteins to
exert their genetic function. This could be exploited thera-
peutically by the introduction of double-stranded oligodeox-
ynucleotides as anti-protein agents or 'traps' for molecules
required for reading the genetic programme encoded in the
genes. Potential targets are gene-specific transcription factors
and the DNA or RNA polymerases themselves. This app-
roach has been used to modulate expression of a heat shock
gene in human T cells by introduction of a synthetic 14 base
pair sequence selected from the enhancer region of the gene
(Harel-Bellan et al., 1989).
Much of the experimental work in the antisense field, in
particular studies of cells in tissue culture, has been done
either by the addition of exogenous synthetic oligodeoxy-
nucleotides to the culture medium, or by the use of endo-
genous antisense genes borne on transient expression vectors
or as integrated trans-genes. Both techniques have achieved
some success in model systems and both have attractions as
potential therapeutic approaches. Synthetic oligodeoxynu-
cleotides are small molecules which could be administered
topically or parenterally while the genetic antisense agents
could be melded with the current 'gene therapy' approaches
to cancer currently under consideration (Gutierrez et al.,
1992).
Targets for antisense therapy in cancer cells
Recent years have seen an explosion in knowledge of the
features which distinguish a cancer cell from its normal tissue
counterpart. Informational drugs which can interfere with the
deregulated flow of genetic information may find their best
targets where there is no normal counterpart with which to
interfere. Clearly such a situation is presented in viral disease,
and indeed encouraging results have been achieved with the
use of antisense approaches to human immunodeficiency
virus (HIV) and Herpes simplex virus (HSV) therapy (for
review see Cohen, 1991). In the context of cancer, novel
sequences are generated from within the cell by mutational
processes such as chromosomal translocation or rearrange-
ment. In a number of cases such mutations are known to
produce novel fusion proteins with transforming properties
(for instance, p2IOtbcr/abl). Mutational processes which result in
single point mutations can lead to activation of some proto-
oncogenes producing dominantly acting, transforming alleles
(for instance, ras oncogenes).
Detailed knowledge of the sequence rearrangements which
occur offers an opportunity to design antisense agents to
block the expression of the aberrant new allele. Examples of
this would include t(9;22) (the Ph chromosome), which gives
rise to the fusion gene bcr-abl in chronic myelogenous leu-
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kaemia and in some forms of acute lymphocytic leukaemia.
Based on the work of Szczylik et al. (1991) and others,
antisense therapy has its first clinical application within the
context of a bone marrow-purging programme in the treat-
ment for Ph-positive leukaemia.
Other specific translocations have also been identified
which offer potential targets for an antisense approach. These
include the t(14;18) in B-cell lymphoma, where a bcl-2/
immunoglobulin gene fusion is formed. Also the t(l5;17) in
acute promyelocytic leukaemia where the genes for the
retinoic acid receptor ot and the zinc finger protein PML
become fused.
Many genes involved in cancer exert their effect by over-
expression, or temporally inappropriate expression, while
their gene products are structurally normal. These could all
be considered as potential targets. Examples include c-fos,
c-myc, N-myc, c-erbB-2 and the nucleolar antigen p120.
Other genes of this category would include those capable of
participating in autocrine and paracrine signalling loops. Pro-
teins such as the fibroblast growth factors, the haemopoietic
colony-stimulating factors, interleukins and of course their
respective receptors fall into this class. Antisense approaches
have been used to down-modulate the expression of several
genes in vitro, including some of the above examples (Dol-
nick, 1991; Helene & Toulme, 1990; Stein & Cohen, 1988).
There are important caveats to the notion that a single
gene product provides a clinically useful target. The cancer
cell is often not the end-point of a strict linear pathway.
Carcinogenesis is a dynamic process involving clonal evolu-
tion and tumor heterogeneity. For example, the acquisition
of a particular activated oncogene may be an important
event during tumour initiation or establishment, but may no
longer be required for the survival of a fully malignant
metastatic cell. The window of opportunity for intervention
with an agent designed to interfere with that oncogene may
have passed, possibly years previously, during the pre-clinical
phase of the disease. We are not yet at a stage where we can
say how great a potential problem this will be. The first goal
of this technology is to identify which oncogenes are domi-
nant and thus present themselves as useful therapeutic
targets.
A further caveat to the potential application of nucleic
acid-based strategies is the fact that many human tumours
arise as much because of a reduction or complete loss of
specific gene expression as because of overexpression. Most
tumour suppressor genes are probably inappropriate candi-
dates for strategies which seek to nullify gene expression.
However, the identification of dominant negative mutations
in some genes such as p53 and the recognition ofgenes which
encode factors which reduce tumour suppressor activity (for
instance MDM2 which can bind p53) may provide targets for
intervention.
What end-points can we seek with antisense therapy?
Down-regulation of a dominant oncogene, or the interrup-
tion of an autocrine or paracrine signalling loop, could be
predicted to by cytostatic and not necessarily cytotoxic. This
will mean that an antisense agent given exogenously will
require repeated administration at appropriate intervals to
ensure a continous suppression of tumour growth.
One might prefer to deliver the agent to a target whose
down-regulation would produce differentiation, for example
c-myb in macrophage differentiation. Better still one might
find a target whose down-regulation would induce apoptosis
and a tumour-killing effect, such as the bcl-2 gene. It may
also be clinically useful to inhibit the metastatic potential of
the tumour. The recent work of Arch et al. (1992) showing
that the expression of a variant CD44 antigen can confer
metastatic properties on non-tumorigenic cell lines, and that
expression of this variant can be detected in the margins of
colorectal tumours provides an attractive and useful possi-
bility for down-modulation by an antisense approach.
A third notional target area would be what Dolnick (1991)
has termed 'host-directed' targets. Examples would include
down-modulation of the MDRI gene increasing the sensiti-
vity of the target tissue to conventional cytotoxic drugs.
Alternatively, suppression of enzymes for drug activation
selectively in normal tissues cpuld allow increased doses of
cytotoxics to be given for the tumour. One study has shown
that antisense-mediated down-modulation of c-rafl mRNA,
can lead to enhanced radiation-sensitivity and reduced
tumorigenicity in a radiation-resistant human squamous car-
cinoma cell line (Kasid et al., 1989). Similarly, in ovarian
carcinoma cell lines a ribozyme targeting c-fos mRNA caused
potentially useful pleiotropic effects such as reduced expres-
sion of DNA polymerase, and increased sensitivity to cis-
platin (Scanlon et al., 1991).
Types of agent currently under evaluation
Antisense and anti-gene agents currently under test are
single-stranded oligodeoxynucleotides and chiefly their methyl-
phosphonate, phosphorothioate and x-oligodeoxynucleotide
analogues. The structures of these common forms are shown
in Figure 1. Other analogues are undergoing development,
and indeed an approach under intense investigation is the
design of non-nucleotide synthetic structures which mimic
nucleic acids, so called 'plastic DNA' (Uhlmann & Peyman,
1990). Novel oligodeoxynucleotide analogues in which the
phosphodiester backbone is replaced with a polyamide (pep-
tide nucleic acids, PNAs) look particularly promising (Niel-
sen et al., 1991; Hanvey et al., 1992).
A basic principle in the design of antisense molecules is to
achieve a balance between conferring sufficient specificity to
the target sequence and maintaining useful physio-chemical
properties to ensure cell penetration and maintenance of
adequate concentration for the desired biological activity.
Despite the apparently minor structural differences between
the various analogues, clear differences in their activities can
be shown.
The unmodified phosphodiester oligodeoxynucleotides are
fairly readily taken up by cells and are relatively non-toxic in
cell types tested so far. They are very efficient at hybrid
formation and induce RNAse H activity (see later) in hetero-
duplexes with RNA. The major disadvantage of the unmod-
ified oligodeoxynucleotides is their extreme sensitivity to
degradation by cellular and extracellular nucleases. Their
half-life in serum is limited to a few hours, and under some
conditions can be as little as 15min.
The methylphosphonate oligodeoxynucleotides are less sol-
uble than the phosphodiester linkage oligodeoxynucleotides
and the other common analogues, but they have relatively
good cell uptake characteristics with low toxicity and high
stability. The major disadvantage of this class of analogue is
relatively poor hybridisation efficiency and inability to induce
the activity of RNase H.
The phosphorothioate oligodeoxynucleotides would seem
to have properties which combine the best features of the
unmodified and methylphosphonate oligodeoxynucleotides;
good solubility, hybridisation efficacy, RNase H induction,
and nuclease resistance. However, they appear to show
sequence non-specific toxicity in some systems, and are also
less well taken up by cells. Sequence-independent toxicity
may be mediated by competitive inhibition of DNA poly-
merase a and P, and non-competitive inhibition of the -y and
a polymerase (Gao et al., 1992). The inhibitory effects appear
to be related to the total number of thioate linkages and not
the position of the linkages within the chain. Low concentra-
tions of phosphorothioate enhance RNase H cleavage where-
as at concentrations exceeding that ofthe target RNA RNase
H is inhibited, protecting the complementary RNA from
degradation (Gao et al., 1992).
The fourth major type of oligodeoxynucleotide are the
a-oligodeoxynucleotides. In these, the linkage formed by the
deoxyribose with the purine or pyrimidine base in normal
phosphodiester linkages is in the unnatural aposition. Such
a-oligodeoxynucleotides form parallel rather than anti-ANTISENSE TECHNOLOGY FOR CANCER THERAPY 871
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Figure 1 Structure of oligodeoxynucleotides and common analogues. Oligodeoxynucleotide structure showing some of the
common analogues achieved by substitution at the internucleotide phosphate. B =purine or pyrimidine base. 1, 'Natural'
phosphodiester linkage; II, Methylphosphonate linkage; III, Phosphorothioate linkage; IV, Linkage of the a-anomer nucleotide; V,
R = -O-CH3: Methylphosphotriester, R = -O-CH2-CH3: Ethylphosphotriester, R = -NH-CH3: Alkylphosphoramidate, R = Many
other substituents possible.
parallel duplexes with complementary DNA or RNA strands.
These analogues show good solubility and stability. They are
able to hybridise at least as efficiently as the phosphoro-
thioates, but they do not induce RNAse H.
Some workers have exploited 'conjugated' oligodeoxy-
nucleotides, i.e. those with particular reactive groups added
to either the 5' or 3' end. The addition of such moieties to
normal phosphodiester oligodeoxynucleotides to some extent
stabilises them against nuclease attack. Such appendages may
also improve cellular uptake if they are hydrophobic. Fluo-
rescent groups provide markers for uptake and localisation,
or can stabilise hybrid formation by intercalation with a
double-stranded target sequence. Some of the conjugates can
be catalytic centres, promoting strand cleavage at a specific
target. Although such functionalisation is usually at the
expense of Tm or sequence specific recognition, such
approaches have seen particular application in anti-gene
strategies.
An important factor to be considered in the use of some
oligodeoxynucleotide analogues is stereoisomerism. This
problem is raised once substitution at the internucleotide
phosphate is achieved, and is a particular problem where
relatively large substituents, such as the methyl group in the
methylphosphonates, are introduced. Modification at n phos-
phodiester linkages will given given 2' iso-forms. Thus for a
15-mer (14 internucleotide linkages) there will be 32,568
stereoisomers. Not all isomers can bind their complementary
target equally well. Some workers have used affinity purifi-
cation to separate low from high affinity stereoisoforms of
9-mer methylphosphonates (Tidd et al., 1988). Hybridisation
experiments showed the Tm of the high and low affinity
populations to differ by 7.6%.
Peptide nucleic acids are able to invade duplex DNA,
causing displacement of one strand and the formation of a
very stable 'D-loop' which blocks RNA polymerase II-medi-
ated transcription. However, despite the advantage of high
stability in serum and within the cell, there are significant
problems to be overcome. These agents can bind DNA in
either orientation (which increases the potential toxicity) and
binding is relatively poor at physiological salt concentrations.
Ribozymes
A further class of antisense agent which merits consideration
comprises the catalytic RNAs or ribozymes. Their structure
and mode of action are entirely different to the systems we
have described, but the outcome of their application and the
kinds of target to which they might be directed are similar.
Ribozymes are small oligo-ribo-nucleotides which have a
specific base sequence with natural self-splicing activity. This
activity can be directed against virtually any RNA target by
the inclusion of an antisense region into the ribozyme, but at
the moment there is still a need for a consensus GUC
sequence in the target at the desired cleavage site. This, for
instance, precludes being able to design ribozymes which can
target many of the common ras gene mutations, but this
situation may not always hold true. A PCR-based 'in vitro
evolution' technique has been recently shown capable of
producing a population of ribozymes with a 100-fold en-
hancement in target cleavage activity compared to the start-
ing molecule (Beaudry & Joyce, 1992). It may be possible to
use such an approach to alter target specificity to suit any
desired sequence. An example of a typical 'hammerhead'
ribozyme is shown in Figure 2.
A major disadvantage of ribozymes at present is that,
being ribonucleic acids, they are particularly sensitive to
nuclease degradation. Ribozymes are not generally being
considered as agents which may be exogenously administer-
ed. Whilst it should be possible to develop nuclease-resistant
ribonucleotide analogues, present strategies employing rib-
ozymes achieve their delivery by genetic means, in the form
of mini-gene constructs (Cameron & Jennings, 1989). In one
study (Cotten & Birnstiel, 1989), the ribozyme RNA has
been expressed in stablised form as a segment within a
modified tRNA gene.
Anti-gene oligodeoxynucleotides, triple-helix agents
Oligodeoxynucleotides designed as anti-gene agents (those
which target double-stranded DNA) are now usually referred
to as 'triple-helix' formers or agents. It is usual for the
oligodeoxynucleotide to be conjugated with a reactive group
to provide a centre for specific strand cleavage, and also to
stabilise and enhance hybridisation formation. Triple-helix
formation is presently limited to homopurine-homopyrimi-
dine sequences within the target DNA, and many important
regulatory elements do not contain such sites. Moreover,
third-strand binding is sensitive to physiological pH, requires
protonated C residues (a pH effect) and is rapidly desta-
bilised by transcription and DNA replication. The triple helix
may also be susceptible to DNA repair processes within the
cell. However, recent results have shown some relaxation in
the target sequence requirements for third-strand binding.
Some mixed sequence sites may be recognised by oligodeoxy-
nucleotides in which G residues of the incoming third strand
form stable base triplets with T-A base pairs on the target
DNA. This has been shown to occur where the T residues
interrupt a homopurine site (Griffin & Dervan, 1989).
Another approach using pyrimidine oligodeoxynucleotides
linked at their 3' termini has shown that adjacent homo-
purine sites on opposite DNA strands can be successfully
targeted (Horne & Duervan, 1990). The linked oligodeoxy-
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Figure 2 Structure of an H-ras ribozyme. The structure of a ribozyme targeting H-ras mutated at codon 12. The complementary
H-ras RNA (1688-1714) is shown with the GUC cleavage site found in a mutated but not normal H-ras allele (Adapted from
Kashani-Sabet et al., 1992).
nucleotide is seemingly able to bind in the major groove of
both purine strands in the target.
Passively acting (i.e. not containing a reactive group)
triple-helix forming agents have been used to bind regions of
DNA which are not simple homopurine-homopyrimidine
tracts. Cooney et al. (1988) have shown inhibition of c-myc
transcription by the presence of an upstream triple-helix in
an in vitro system. Recently, Mergny et al. (1992) have shown
sequence-specific inhibition of transcription initiation by
triple-helix agents. This in vitro reaction could be greatly
enhanced by the addition of a benzo[e]pyridoindol derivative.
The binding of this agent to the triple-helix enhanced the
stability of the triplex by as much as a 20°C increase in Tm.
Interestingly, some of the benzo[e]pyridoindol derivatives
have themselves shown promise as new anti-tumour agents
(Nguyen et al., 1992), where they may act by interaction with
DNA topoisomerase II/DNA complexes. It remains to be
tested whether or not these agents used in conjunction with
triple-helix forming oligodeoxynucleotides can provide the
basis for specific inhibition of transcription in vivo.
Mechanisms of action
Several potential mechanisms by which antisense agents can
lead to the downregulation of a particular gene can be
identified. The possible mechanisms have been divided into
three classes: passive, reactive and activating processes
(Rothenburg et al., 1989).
A passive process would be one in which the oligodeoxy-
nucleotide exerts its effect by simple blocking of function
through steric hindrance. Such a mechanism could affect
-many aspects of the functioning of an mRNA molecule. For
example, interaction with ribosomes or splicosomes or even
the transport processes from the nucleus to the cytoplasm.
Reactive processes would be where the oligodeoxynucleo-
tide can directly cross-link with the target sequence to
irreversibly block its action or, more favourably, those where
the target sequence is bound and cleaved. While the former
reaction will be stoichiometric, the latter might act
catalytically thereby reducing the amount of compound
required.
An activating process would occur when the heteroduplex
formed between the target and the antisense agent, causes the
activation of endogenous enzymes such as RNAse H to
cleave the RNA or perhaps (in)activation of other stability
modifiers.
Sequence specificity and the significance of RNase H
RNase H digests the RNA component of a RNA-DNA
heteroduplex. Thus in the context of an antisense oligodeoxy-
nucleotide bound to its target mRNA, the RNA will become
inactivated regardless of the position on which the antisense
agent binds the RNA. As this mechanism is catalytic, it has
the advantage that one antisense molecule can inactivate
many target molecules. It is probable that RNase H-mediat-
ed cleavage is the major mechanism by which antisense
effects targeted against the translated region of mRNA are
brought about, although methylphosphonate and 2'-O-allyl
modified phosphodiester oligodeoxynucleotides can produce
translation arrest in vitro via an RNase H-independent
mechanism.
Inhibitory activity of antisense molecules which target the
5' untranslated region of the mRNA are also probably
influenced by RNAse H, to augment the steric effects of
blocking ribosome assembly or passage.
RNase H is an enzyme involved in DNA replication and
as such it is likely to be widely and constitutively expressed.
At the present time, its cellular and tissue distribution (par-
ticularly in tumour tissue) is not well known and may limit
therapeutic approaches based on this mechanism.
A major potential source oftoxic side effects with antisense
agents will result from fortuitous hybridisation with non-
target RNAs. It has been estimated that the oligodeoxy-
nucleotide length required to specify a unique sequence of
human mRNA is 11 nucleotides if the target contains only G
and C residues, and 15 nucleotides for targets containing
only A and T (Helene & Toulme, 1989). Hence the average
shortest unique sequence in the mRNA pool is 13 bases.
There is evidence that a single internal mismatch within a
13-mer will not prevent degradation, indeed Woolfe et al.
(1992) have shown that a complementary sequence of ten
consecutive bases is sufficient to produce antisense degrada-
tion in a Xenopus oocyte system. Any given 13-mer will
contain four different internal 10-mers and so could recog-
nise any many as 76 different complementary sites. Longer
oligomers will contain more internal 10-mers, and since
flanking sequences do not prevent antisense effects (Woolfe et
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al., 1992), increasing the length of an oligomer is likely to
increase rather than decrease the number of RNAs that will
suffer non-specific degradation. However, it should be point-
ed out that experiments with Xenopus oocytes are carried out
at temperatures 15-20° lower than those in mammalian cells.
Hybridisation conditions will be much more restrictive in
mammalian cells and it is unlikely that 10 base pairs out of
13 will be sufficient to induce additional cleavage. Despite
this, such arguments underscore the importance of chain
length in the design of oligodeoxynucleotides.
Problems ofspecificity which apply to oligodeoxynucleotides
and ribozyme-based systems extend beyond statistical estima-
tion of target sequence abundance. Kinetic considerations
such as hybrid stability, rates of formation and dissociation
and even location within particular cellular compartments
will influence the ability of RNase H to degrade non-target
RNAs. Other influential factors which are difficult to predict
include rates of replacement of RNA pools and the accessi-
bility (secondary structure) of the cross-hybridising sequence.
A useful discusson of this area has been given by Herschlag
(1991).
These inappropriate effects due to partial sequence hybrids
are a potential problem for all oligodeoxynucleotides capable
of directing RNase H. One way around this problem (Giles
& Tidd, 1992), is the use of chimeric oligodeoxynucleotides,
containing segments of sequence made up of methylphos-
phonate linkages which do not direct RNase H, surrounding
an 'active window' ofphosphodiester-linked nucleotides cap-
able of directing cleavage.
What effects have been seen with antisence agents?
In general, three types of experimental system have been
exploited in assessing antisense effects. Cell-free translation
systems, Xenopus oocytes and cells grown in tissue culture.
In experiments with cell-free translation systems, the ability
of different antisense agents to inhibit the in vitro translation
of particular mRNAs can be readily assessed. Such experi-
ments have indicated that the best target sites in the mRNA
are at the 5' end, around the initiator AUG codon and the
assembly sites for the ribosome complex. The translation
initiation factors assemble in a process which probably also
requires recognition of the 5' methyl-G cap of mature
mRNA molecules. Antisense molecules complementary to
this region of the message are more active if their sequence
extends to include a short dC tail, presumably capable of
hybridising with the 5' cap (Goodchild et al., 1988).
Successful and specific inhibition of oncogene expression
and tumour cell growth has been reported with antisense
oligodeoxynucleotides against the message for c-myc (Wick-
strom et al., 1988; Holt et al., 1988), c-myb (Gewirtz &
Calabretta, 1988), PCNA cyclin (Jaskulski et al., 1988),
retinoic acid receptor a(Cope & Wille, 1989) and c-fos using
a ribozyme approach (Scanlon et al., 1991). The p120
nucleolar antigen expressed in most human malignant
tumours, and of some prognostic significance in breast
cancer, has been inhibited to biological effect by a genetic
antisense approach (Perlaky et al., 1992).
Examples of antisense inhibition of autocrine stimulation
loops have also been produced. Agents targeted to CSFI and
its receptor c-fms can inhibit cell proliferation (Birchenall-
Roberts et al., 1990; Wu et al., 1990). Similarly, antisense
inhibition has been reported for interleukins 2, 4 and 6
(Harel-Bellan et al., 1988; Schwab et al., 1991), EGF receptor
(Moroni et al., 1992) and basic fibroblast growth factor
(Murphy et at., 1992).
It may be significant that in most of these cases the
half-life of the mRNA is less than an hour and that complete loss of mRNA translation was not achieved, nor seemingly required, for a biological effect to be scored.
In the case of the ras family ofproto-oncogenes, where the
turnover of the protein product and its mRNA is compara- tively slow, biological effects have also been noted. All three
ras genes have been targeted by antisense approaches. N-ras
has been down-modulated in haemopoietic cells in vitro
(Skorski et al., 1992). Ki-ras has been targeted using a
genetic antisense approach (Mukhopadhyay et al., 1991) in
which a human lung cancer cell line containing a homozy-
gous Ki-ras mutation was engineered to express a Ki-ras
antisense cDNA. Cells remained viable, but showed a 3-fold
reduction in growth rate and concomitant reduction in
tumorigenicity.
The Ha-ras gene has seen the most experimental attention,
targeted by various antisense oligodeoxynucleotide analogues
(Brown et al., 1989; Daaka & Wickstrom, 1990; Chang et al.,
1991), and in some studies by ribozymes (Kashani-Sabet et
al., 1992; Koizumi et al., 1992). A remarkably high degree of
specificity was achieved for mutant-specific antisense oligo-
deoxynucleotides using a cell-free system targeting Ha-ras
(Saison-Behmoaras et al., 1991). The 9-mers used in this
study were linked to an intercalating agent (5'-acridine) and/
or a hydrophobic tail (3'-dodecanol). Addition of such
appendages increased the binding affinity of these short
oligodeoxynucleotides resulting in RNase H-dependent specific
inhibition of the mutant p21 mRNA translation, whilst the
normal message was only marginally affected. Growth inhibi-
tion was achieved when similar agents were added to T24
bladder carcinoma cells, under conditions where cells con-
taining wild-type Ha-ras were not affected. Similar results
were produced using other analogues and cell lines (Brown et
al., 1989; Daake & Wickstrom, 1990; Chang et al., 1991).
For all of these studies, including the genetic antisense inhibi-
tion of Ki-ras (Mukhopadhyay et al., 1991), cell lines were
used which were expressing high levels of the mutant form of
protein, in the absence of the competing normal mRNA. The
next stage will be to show that similar effects can be achieved
in cells expressing more physiological levels and ratios of
mutant to wild-type p21.
Delivery systems for antisense agents
It is obvious that the therapeutic applications of antisense
nucleic acids are at a very early level in development. Manu-
facturing issues such as cost factors and which analogue(s)
warrant scale-up production of synthesis are a long way off.
Despite this, some consideration of the pharmacological
aspects of antisense therapeutic strategies is warranted.
Exogenous infusion is the most direct method of delivery
for any drug. Oligodeoxynucleotides are apparently cleared
from the circulation in mice fairly rapidly and distributed to
most tissues (Agrawal et al., 1992; Zon, 1989), and prelim-
inary toxicological studies have shown that a dose of 100 mg
kg-' body weight of phosphorothioate oligodeoxynucleotide
for 14 days is non-toxic in mice. In most tissues the oligo-
deoxynucleotide was quite stable, but in liver and kidney
there was apparent extension of the synthetic molecule.
Much of the administered dose is excreted in the urine over 2
or 3 days (more rapidly for oligodeoxynucleotides with phos-
phodiester linkages) and very little in the faeces.
Oligodeoxynucleotides are undoubtedly able to enter living
cells. However there is evidence that much of the material
remains sequestered in the extracellular environment of an
endosome. It is probable that a combination of mechanisms
lead to uptake, including endocytosis, and receptor-mediated
internalisation. The presence of hydrophobic moieties linked
to the 5' or 3' end of an oligodeoxynucleotide can greatly
influence the rate of uptake into the cell and its intracellular
distribution. One recent study (Boutorine et al., 1992) show-
ed that the addition of a porphyrin to the terminal phosphate
of a 17-mer caused a 6-fold increase in uptake into T24 cells,
while a 30-100 fold increase was achieved by addition of
cholesterol to the oligodeoxynucleotide. On the down-side
however, addition of cholesterol onto the oligodeoxynucleo-
tide will dramatically reduce the Tm of the molecule.
The idea of including a terminal modification to enhance
uptake has been taken a stage further by the report of
successful delivery of antisense c-myb oligodeoxynucleotides
to HL60leukaemia cells, via receptor-mediated uptake. In874 G. CARTER & N.R. LEMOINE
this study (Citro et al., 1992) the oligodeoxynucleotide was
linked to a transferrin/polylysine complex. The interaction of
this conjugate with the transferrin receptor was demonstrated
by competitive inhibition with a fluoresceinated anti-
transferrin receptor monoclonal antibody. Cells treated with
the conjugated antisense c-myb agent showed loss of pro-
liferation and viability greater than that exhibied by cells
which had been treated with unconjugated antisense oligo-
deoxynucleotides. Such a study indicates that other ligand-
receptor combinations might also be useful in the selective
delivery of antisense oligodeoxynucleotides.
In studies of cellular uptake, it is important to show that
the internalised oligodeoxynucleotide is intact. As has been
pointed out by Tidd (1990), a particular difficulty when using
oligodeoxynucleotides which have been 32P end-labelled is the
removal of label by phosphomonoesterase and incorporation
of the radioactivity into cellular pools. Difficulties can also
arise when using fluorescent labels as reporter groups. Tidd
(1990) has suggested that certain results (Stein et al., 1988;
Loke et al., 1988; 1989) using flow cytometry to follow a 5'
acridine label can be explained on the basis of degradative
mechanisms preceding uptake. Labelling of phosphorothioate
oligodeoxynucleotides with 35S has proved effective in vitro
(Agrawal et al., 1992).
The subsequent distribution of the oligodeoxynucleotide
within the cell may lead to loss of activity, for example if the
molecule is locked inside endosomal vesicles. Some studies
have been carried out on the effectiveness of using lipofusion
as a method for introducing oligodeoxynucleotides into the
cytoplasm. Not only does this method allow for the delivery
of larger and/or modified oligodeoxynucleotides, it also pro-
tects the agent from extracellular degradation. However, lipo-
some contents are primarily delivered to endosome/lysosome
compartments where their contents are subjected to enzym-
atic degradation. Use of pH-sensitivie liposomes which
release their contents following acid pH-induced fusion may
circumvent this problem. Such vesicles can be made to pro-
vide receptor-mediated endocytosis and effective cytoplasmic
release (Conner & Huang, 1986). Loke et al. (1988) have
used liposome fusion to deliver antisense phosphorothioate
oligodeoxynucleotides to haemopoietic cells growing in cul-
ture. In these experiments c-myc mRNA was targeted result-
ing in reduction in c-myc protein level, a reduced rate of
DNA synthesis and growth inhibition.
There is an increasing optimism that antisense molecules
could be delivered as genetic antisense agents, carried and
expressed by engineered retroviruses, or delivered by trans-
fection in vitro into cells which are re-infused into the patient.
To date 15 clinical trials employing retroviral delivery
systems have been approved in the USA (Miller, 1992). Such
vectors are highly efficient at delivering genes into dividing
cells. Gutierrez et al. (1992) have outlined a number of
conditional promoters which might be included in a construct
to provide tissue-specific expression of any gene or anti-gene
vectored into a cell which is expressing the appropriate tran-
scription machinery. Examples of such promoters include
tyrosinase for melanoma, prostate-specific antigen for pro-
static disease, polymorphic epithelial mucin for breast and
pancreatic cancers. Much work remains to be done before
such systems become suitable for clinical use.
Concerns and conclusions
There are important reservations to be addressed before we
can say that antisense reagents really offer useful new
therapeutic opportunities. If we examine some of the above
mentioned effects, aside from establishing the principle that
antisense strategies can work in certain highly controlled
(and carefully chosen) model systems, is there really any
prospect that a new therapeutic principle has been estab-
lished? Clearly biological responses in terms of 'reduced pro-
liferation', or differentiation have undoubtedly been shown.
However, with a few exceptions, virtually no studies provide
direct evidence that sequence-specific recognition by the
oligodeoxynucleotide was responsible for the biological
phenotype(s) observed. Also, what of the magnitude of the
responses, are they significantly greater than those achievable
with conventional approaches? There will be little advantage
in gaining increased specificity with the new agents at the
expense of poor efficacy. Questions of cost effectiveness can-
not be addressed until scaled-up production of the appropri-
ate agents has been achieved. We have little idea if these
agents are likely to be immunogenic or toxic in long term
administration. We would predict that the types of synthetic
oligodeoxynucleotide in experimental use now are unlikely to
be those which ultimately find clinical use. Other nucleic acid
analogues, 'plastic-DNA', PNA and ribo-oligomers, all have
potential advantages which need to be explored in vitro and
in vivo. The genetic delivery of antisense technology by retro-
viruses and possibly minichromosomes or other systems
looks set to make advances in the future.
We have paid some attention to the types of target that
may be useful in ablating cancer cells. High prevalence of a
given molecular lesion in a particular tumour may suggest it
as a tempting target, but its ablation may be sufficient to
destroy the cell. Much more basic information about both
the disease and antisense technology itself is still required
before we can offer new therapeutic agents for the treatment
of cancer, but the signs are hopeful.
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